Sutro Biopharma, Inc. (STRO) - Q2 2024 10-Q Summary
Business Context and Reporting Period
Sutro Biopharma, Inc. is a clinical-stage oncology company developing site-specific antibody drug conjugates (ADCs) using its proprietary XpressCF and XpressCF+ platforms. The company operates in a single segment focused on biopharmaceutical product development. This report covers the quarterly period ended June 30, 2024. As of this date, the company had no products approved for commercial sale.
Key Financial Metrics
| Metric (in thousands) | Q2 2024 | Q2 2023 | 6 Months 2024 | 6 Months 2023 |
|---|---|---|---|---|
| Revenue | $25,706 | $10,412 | $38,714 | $23,086 |
| Net Loss | $(48,018) | $(38,524) | $(106,231) | $(88,574) |
| Loss Per Share (Basic/Diluted) | $(0.59) | $(0.64) | $(1.49) | $(1.49) |
| Cash, Cash Equivalents, and Marketable Securities | $375,568 | $333,681 | $375,568 | $333,681 |
| Accumulated Deficit | $(665,639) | $(541,189) | $(665,639) | $(541,189) |
| Deferred Royalty Obligation | $163,905 | $149,114 | $163,905 | $149,114 |
Note: Cash, cash equivalents, and marketable securities are derived from the balance sheet (Cash $90,788 + Marketable Securities $284,780). Equity securities (Vaxcyte) of $50,424 are held separately.
Material Changes vs. Prior Period
- Revenue Growth: Revenue increased 147% year-over-year for Q2 2024 and 68% for the six-month period. This was primarily driven by a $17.8 million cumulative catch-up adjustment in revenue from the Astellas collaboration due to a contract modification (Astellas elected not to nominate a third target program).
- Operating Expenses: Total operating expenses increased 31% in Q2 and 29% for the six months ended June 30, 2024. Research and Development (R&D) expenses rose significantly (49% in Q2, 47% for six months) due to increased external services, specifically contract manufacturing organization (CMO) activities, and higher clinical development costs.
- Non-Cash Interest Expense: Non-cash interest expense related to the sale of future royalties increased substantially to $7.3 million in Q2 2024 (from $0.4 million in Q2 2023) and $14.5 million for the six months (from $0.4 million in the prior year). This reflects the accretion of the deferred royalty obligation from the 2023 Blackstone transaction.
- Capital Raises: In April 2024, the company completed an underwritten offering raising approximately $75.0 million (gross) and received $25.0 million from Ipsen Biopharmaceuticals, Inc. (USA) in connection with a new license agreement.
Guidance, Outlook, and Risks
- Liquidity: Management believes existing cash, cash equivalents, marketable securities, and equity securities ($426.0 million total) will fund operations for at least 12 months following the filing date. However, the company expects to continue incurring substantial losses and will need to raise additional capital in the future.
- Product Pipeline: The most advanced asset, STRO-002 (luvelta), is in a Phase 2/3 trial (REFRαME-O1) for platinum-resistant ovarian cancer. Enrollment for Part 1 was completed in April 2024, and Part 2 enrollment has begun. The company expects to present updated data from the bevacizumab combination study at the 2024 ESMO Congress.
- Collaborations: Significant revenue is tied to collaborations with Astellas, Ipsen, Merck, and Tasly. The Astellas contract modification resulted in immediate revenue recognition but reduced the long-term scope of that specific agreement.
- Risks: Key risks include the failure of product candidates in clinical trials, the inability to secure additional funding on acceptable terms, reliance on third-party manufacturers, and the impact of the non-cash interest expense on the deferred royalty obligation. The company also faces risks related to the valuation of its Vaxcyte equity investment.
Investor Verification Checklist
- Revenue Recognition: Verify the accounting treatment and sustainability of the $17.8 million catch-up adjustment from the Astellas contract modification.
- Cash Burn Rate: Assess the trajectory of operating cash burn given the increase in R&D expenses and the timeline for potential commercialization.
- Deferred Royalty Obligation: Review the assumptions used to calculate the non-cash interest expense on the Blackstone royalty sale, as this significantly impacts reported net loss.
- Clinical Milestones: Monitor the progress and data readouts from the REFRαME-O1 Phase 2/3 trial for luvelta, which is critical for future valuation.
- Capital Requirements: Evaluate the sufficiency of the current cash runway ($426 million) against the projected costs of advancing multiple clinical programs and the potential need for further dilutive financing.